Co-Diagnostics, Inc. (CODX)
| Market Cap | 338.42M |
| Revenue (ttm) | 47.52M |
| Net Income (ttm) | 27.94M |
| Shares Out | 28.08M |
| EPS (ttm) | 1.12 |
| PE Ratio | 10.60 |
| Forward PE | 6.16 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $11.89 |
| Previous Close | $11.82 |
| Change ($) | 0.08 |
| Change (%) | 0.63% |
| Day's Open | 11.90 |
| Day's Range | 11.41 - 12.11 |
| Day's Volume | 1,249,280 |
| 52-Week Range | 1.88 - 30.80 |
This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between commo...
These winners are positioned for gains even after COVID.
SALT LAKE CITY, Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mol...
SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mol...
These companies are developing highly competitive vaccines and diagnostics.
Not all of them were COVID-19 vaccine makers.
Investors in fast-moving biotechs made out like bandits.
Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profi...
These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.
SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molec...
The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molec...
The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?
SALT LAKE CITY, Nov. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molec...
The company badly missed Wall Street earnings estimate for the third quarter.
SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic ...
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2020 Results - Earnings Call Transcript
SALT LAKE CITY, Nov. 16, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic ...
The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic ...
SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic ...
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
SALT LAKE CITY, Utah, Nov. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagno...
These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.
Co-Diagnostics has had a wild run this year. Is it too late to get in on this booming biotech stock?
CoDiagnostics, Inc. (CODX) closed the most recent trading day at $14.42, moving +0.07% from the previous trading session.
Shares of the COVID-19 test maker remain very volatile.
Investors need to pay close attention to Co-Diagnostics (CODX) stock based on the movements in the options market lately.
SALT LAKE CITY, Oct. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, anno...
These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.
Massive amounts allocated to the purchase of fixed assets may anticipate higher stock prices
SALT LAKE CITY, Sept. 24, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, an...
The company's stock had a huge week after announcing that Arches Research has signed a deal to use its coronavirus test kit.
SALT LAKE CITY, Sept. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
Even top diagnostic test producers got hit hard in late August.
Co-Diagnostics, Inc. (NASDAQ: CODX) shares shot up on Tuesday after the company announced that it has entered into an agreement with Arches Research to expand Arches’ COVID-19 testing services...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that its subsidiary, Arches R...
The most likely culprit: continued concerns about a competitor's new product.
SALT LAKE CITY, Sept. 1, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
These are the small cap stocks with the best value, fastest growth, and most momentum for September.
Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.
Blame it on Abbott.
It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.
SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
SALT LAKE CITY, Aug. 20, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
Co-Diagnostics Inc. (CODX) CEO Dwight H Egan on Q2 2020 Results - Earnings Call Transcript
Los Angeles, California--(Newsfile Corp. - August 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diag...
About CODX
Co-Diagnostics, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
| Industry Diagnostics & Research | IPO Date Jul 12, 2017 |
| CEO Dwight Egan | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol CODX |
Financial Performance
In 2019, Co-Diagnostics's revenue was $214,974, an increase of 438.63% compared to the previous year's $39,911. Losses were -$6.20 million, -1.21% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Co-Diagnostics stock is "Buy." The 12-month stock price forecast is 31.00, which is an increase of 160.72% from the latest price.